Skip to main content
Equibles
AURA logo

AURA · Aura Biosciences, Inc. · Metrics

Track AURA — free

Use AURA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AURA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.30 +0.12 (+1.94%) At close · Oct 27 Q1 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$653.34M
Shares
103.70M
Volume · Oct 27 680.27K Avg daily vol (3M) 850.19K

AURA metrics

65 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.30
Market cap
$653.34M

Price action

20 metrics
Price change (1W)
-1.7%
Price change (30D)
+0.5%
Price change (3M)
-13.7%
Price change (6M)
-11.2%
Price change (YTD)
+13.4%
Price change (1Y)
+5.5%
Trailing year
Price change (5Y)
—
52-week high
$8.90
52-week low
$4.97
Change from 52-week high
-30.6%
Change from 52-week low
+24.3%
Annualized volatility
55.8%
Annualized volatility (3M)
43.3%
Beta
1.0
RSI (14D)
42.8
Price vs SMA 50
-9.2%
Price vs SMA 200
-7.7%
Avg volume (3M)
843,598
Relative volume
1.1
Average dollar volume
$5.80M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
103.70M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.0
reciprocal yield 49.2%
FCF yield
-16.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-20.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-27

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$138.08M
Net income (TTM)
−$131.01M
Trailing 12 months
Diluted EPS (TTM)
$-1.72
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.85
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.76
Operating cash flow per diluted share (TTM)
$-1.40
Free cash flow per diluted share (TTM)
$-1.40
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$1.40
Stock compensation per diluted share (TTM)
$0.29
Book value per share
$2.15

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+63.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-41.6%
Return on assets
-37.6%
Debt / equity
—
Current ratio
16.8
EBITDA (TTM)
—
Free cash flow (TTM)
−$103.35M
Quick ratio
16.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$67.84M
Latest balance sheet
Cash & equivalents
$67.84M
Total assets
$348.13M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$103.01M
Capital expenditures (TTM)
$344,000
R&D (TTM)
$102.78M
SG&A (TTM)
—
Stock compensation (TTM)
$23.16M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
148
13F filer change QoQ
+21
Institutional ownership
92.1%
Conviction holders (share of 13F filers)
1.4%
Crowding (high-turnover and private-fund holders)
52.8%
Private-fund adviser ownership
52.4%
Active holders' share change QoQ
+150.6%
Holder tenure
6.6
Price vs estimated holder cost
-12.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
8.7%

Short interest

3 metrics
Short interest
10.5%
Latest settlement · 10.6 days to cover
Days to cover
10.6d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1501796 CUSIP 05153U107 13F (30d) 21 filings 21 filers Visit website Investor relations